香港股市 已收市

Aytu BioPharma, Inc. (AY20.SG)

Stuttgart - Stuttgart 延遲價格。貨幣為 EUR。
加入追蹤清單
2.62000.0000 (0.00%)
收市:08:00AM CEST

Aytu BioPharma, Inc.

Denver Corporate Center III
7900 East Union Avenue Suite 920
Denver, CO 80237
United States
720 437 6580
https://aytubio.com

版塊Healthcare
行業Drug Manufacturers - Specialty & Generic
全職員工150

高階主管

名稱頭銜支付行使價出生年份
Mr. Joshua R. DisbrowChairman & CEO660.51k1975
Mr. Mark K. Oki CPACFO, Secretary & Treasurer487.77k1969
Mr. Greg PyszczymukaChief Commercial Officer489.78k1980
Ms. Margaret CabanoVice President of Operations
Mr. Jarrett T. Disbrow Ph.D.Chief Business Officer & President of Consumer Health331.19k1975
Mr. Russ McMahenSenior Vice President of Research & Development
Mr. Ryan J. Selhorn CPAExecutive VP of Finance & Business Optimization1982
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.

公司管治

截至 無 止,Aytu BioPharma, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。